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Abstract The structure of the enzyme glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) from glycosomes of the parasite
Trypanosoma cruzi, causative agent of Chagas’ disease, is
reported. The final model at 2.8 Aî includes the bound cofactor
NAD+and 90 water molecules per monomer and resulted in an
Rfactor of 20.1%, Rfree = 22.3%, with good geometry indicators.
The structure has no ions bound at the active site resulting in a
large change in the side chain conformation of Arg249 which as a
consequence forms a salt bridge to Asp210 in the present
structure. We propose that this conformational change could be
important for the reaction mechanism and possibly a common
feature of many GAPDH structures. Comparison with the
human enzyme indicates that interfering with this salt bridge
could be a new approach to specific inhibitor design, as the
equivalent to Asp210 is a leucine in the mammalian enzymes.
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1. Introduction
Chagas’ disease, caused by the protozoan Trypanosoma cru-
zi, is estimated to a¡ect some 16^18 million people, mostly
from South and Central America, where 25% of the total
population are at risk [1]. About 3 million of the infected
people have developed severe complications, characterised
by chronic cardiopathy, digestive lesions and neurological dis-
orders, causing 45 000 deaths per year and a loss of approx-
imately 3 million disability-adjusted life years (DALYs). In-
creasing incidence in urban areas of North America has been
reported, as a consequence of the £ux of immigration from
the south. Control of the insect vector (Triatoma infestans) in
endemic areas has led to a virtual elimination of transmission
by insect bites and as a consequence blood transfusion and
congenital transmission are currently the major causes for the
spread of the disease. Since the discovery of the disease by the
Brazilian sanitary physician Carlos Chagas, in 1909, many
attempts at treatment have been made, but no e¡ective drug
has so far been found. Besides low e⁄cacy, the drugs cur-
rently available, nifurtimox and benzonidazole, have strong
side e¡ects [2]. The clear need for the development of new
drugs against Chagas’ disease has stimulated us to initiate a
project aimed at the discovery of highly speci¢c inhibitors that
could be used as lead compounds through the structure-based
design of molecules that could interfere with speci¢c targets of
the trypanosomal metabolism.
In 1977, Opperdoes and Borst discovered that the blood-
stream form of parasites of the family Trypanosomatidae pos-
sesses a microbody-like organelle, the glycosome, where gly-
colysis takes place. The bloodstream form of the related
parasite Trypanosoma brucei, the causative agent of sleeping
sickness, has no functional tricarboxylic acid cycle and is
highly dependent on glycolysis for ATP production [3]. This
great dependence on glycolysis as a source of energy makes
the glycolytic enzymes attractive targets for trypanocidal drug
design. Indeed, three enzymes of this metabolic pathway in T.
brucei have had their three-dimensional structures determined,
triosephosphate isomerase (TIM) [4], glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) [5] and phosphoglycerate kin-
ase (PGK) [6]. One of these proteins, glycosomal GAPDH,
shows potential target sites with signi¢cant di¡erences com-
pared with the homologous human enzyme, and inhibitors
have been designed, synthesised and tested [7,8]. These prom-
ising results prompted us to initiate the structural study of the
same enzyme from Trypanosoma cruzi which is reported here.
Glycolysis is also a very important metabolic process in the
mammalian stages of this latter trypanosomatid species [9].
The enzyme GAPDH is a homotetramer of molecular mass
approximately 156 kDa, whose physico-chemical properties
are conserved in most species [10]. GAPDH catalyses the ox-
idative phosphorylation of glyceraldehyde-3-phosphate (GAP)
to 1,3-bisphosphoglycerate (BPG). Although the reaction
mechanism has been intensively investigated [11^13], there is
no general agreement on the molecular mechanisms involved
in the regulation of the binding of the substrate to and the
release of the product from the active site.
The 3D structures of GAPDH from several other species
have been determined crystallographically, including lobster
[14], human [15], Bacillus stearothermophilus [16], T. brucei
[5], Thermotoga maritima [17], Thermus aquaticus [18], Esche-
richia coli [19] and Anas sp. [20]. As a common feature of
several of these structures, two sulphate ions were found in
each monomer, bound at the catalytic site. These ions where
thought to occupy the positions of the two phosphate ions
involved in the reaction, respectively the phosphate from the
substrate (Ps) and the inorganic phosphate (Pi) which is added
to the 1-position of the substrate during the reaction. Re-
cently, the crystal structure of GAPDH from Leishmania mex-
icana was determined, in the presence of phosphate instead of
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sulphate [21]. It was found that the binding site for Ps is
essentially the same as that observed for the corresponding
sulphate ion in the other structures. In contrast, the Pi site
was found to be displaced by 2.9 Aî and closer to the catalytic
histidine residue, with the authors suggesting that this position
is more likely to be the active one. The structure of the apo-
enzyme (in the absence of both cofactor and anions) from B.
stearothermophilus [16] and lobster [14], and more recently the
structures of the enzymes from E. coli and Thermus aquaticus
(complexed with NAD but in the absence of ions), have led
to speculations regarding the molecular mechanism of the re-
action pathway.
In this work we present the crystallographic structure of
GAPDH from T. cruzi. The enzyme was also crystallised in
the absence of sulphate or phosphate ions and this fact has led
to new insights into the possible role of several residues in the
regulation and stabilisation of substrate binding and the re-
lease of the reaction product.
2. Materials and methods
2.1. Preparation and puri¢cation of T. cruzi GAPDH
Recombinant T. cruzi GAPDH (TcGAPDH) was prepared and
puri¢ed according to a modi¢cation of a previously reported proce-
dure [22]. TcGAPDH-overproducing E. coli were grown at 37‡C in
LB medium supplemented with glycerol 1%, malic acid 0.4%, casami-
no acids 0.1%, ampicillin 100 Wg/ml and tetracycline 12.5 Wg/ml. When
the OD600 was 0.8 the expression of T. cruzi GAPDH was induced by
0.4 mM IPTG at 20‡C overnight. The lower temperature during ex-
pression was essential for recovering large quantities of soluble and
fully active enzyme. The cells were lysed by sonication and the lysates
were centrifuged at 20 000Ug for 20 min. The supernatant was frac-
tionated by ammonium sulphate precipitation (50% saturated) and the
resultant mixture centrifuged at 2000Ug for 20 min. The supernatant
was further puri¢ed by hydrophobic chromatography on a phenyl-
sepharose column in which TcGAPDH was eluted with a decreasing
(NH4)2SO4 gradient. Eluted fractions containing TcGAPDH were
pooled and dialysed against (NH4)2SO4-free 25 mM Tris-HCl pH
7.8 bu¡er. The dialysed sample was subsequently further puri¢ed by
cation-exchange chromatography on a column of phospho ultrogel in
which TcGAPDH was eluted with an increasing KCl gradient. Frac-
tions containing GAPDH activity were pooled and dialysed against 25
mM Tris-HCl pH 7.8 bu¡er, containing 500 mM ammonium sul-
phate, 2 mM NAD, 1 mM azide, DTT and EDTA and concentrated
using an Amicon concentrator to a ¢nal concentration of 9 mg/ml.
The homogeneity of the enzyme was evaluated by SDS-PAGE.
2.2. Crystallisation of T. cruzi GAPDH
Crystals of T. cruzi GAPDH were grown at 4‡C by hanging drop
vapour di¡usion, using a protein solution at 9 mg/ml in the above
described dialysis bu¡er and a reservoir solution of 0.1 M sodium
cacodylate pH 6.5, 18% polyethylene glycol 8000 and 0.2 M calcium
acetate. The crystals grow to a size of 0.1U0.2U0.2 nm within 10
days, frequently mixed with salt crystals resulting from the reaction of
the ammonium sulphate with calcium acetate. The crystals belong to
the space group P1 with unit cell dimensions a = 88.1 Aî , b = 124.6 Aî ,
c = 85.4 Aî , K= 101.2‡, L= 112.9‡, Q= 83.6‡. Crystal content analysis
indicates two tetramers in the unit cell, resulting in a Vm value of
2.53 Aî 3/Da, close to the average value for other protein crystals [23].
2.3. Data collection
Di¡raction intensities were collected with the crystals cooled to 4‡C,
using a Rigaku RU-200 generator and an R-AXIS II area detector.
The crystals are very fragile and sensitive to variations in temperature
and precipitant concentration. Four crystals were used, totalling 89
di¡raction images of 2‡ oscillation. The program PROCESS [24] was
used to index the images, integrate the intensities, and scale and merge
the data. A total of 73 595 re£ections were measured between 15 and
2.8 Aî resolution and reduced to 54 184 unique re£ections (67.1% com-
pleteness). The data set has an Rsym of 0.125 on intensities (0.20 in the
last resolution shell 2.95^2.8 Aî ).
2.4. Structure determination and re¢nement
The structure of T. cruzi GAPDH was determined by molecular
replacement. The search model used was the T. brucei GAPDH crys-
tal structure deposited in the PDB (1GGA), from which the NAD
cofactor, sulphate ions and water molecules were removed. The over-
all sequence identity between TcGAPDH and TbGAPDH is 90% [22].
The program AMoRe [25] was used for the rotation and translation
functions using the data from 15 to 3.5 Aî resolution. Two solutions
for the rotation matrix were determined which are associated with the
two T. cruzi GAPDH tetramers in the primitive cell. With one of the
tetramers centred at the origin, the translation function for the second
tetramer presented a unique solution with a correlation coe⁄cient of
58.4%, a value double that of the second highest peak. This solution
resulted in a crystalline packing which presented no steric hindrance,
good intermolecular contacts and a compatible solvent content.
The re¢nement of the structure was performed using the X-PLOR
program [26] including data in the range 8.0^2.8 Aî . The search model
after rotation and translation, was submitted to rigid body re¢nement,
considering the eight subunits as independent rigid structures. From
this point onwards, strict non-crystallographic symmetry was im-
posed. After determining the matrix and vectors which superimpose
one independent subunit to the other seven, a molecular mask for one
of the subunits was constructed using the program MAMA [27]. Elec-
tron density maps w(2Fo3Fc) for the eight subunits were calculated
using the package of programs CCP4 [28]. The 8-fold averaged map
was then calculated starting from the molecular envelope and the
individual electron density maps using the RAVE package [29]. The
averaged map analysis allowed the unambiguous ¢tting of the correct
T. cruzi residues into the initial T. brucei GAPDH model, using the
program O [30].
After this procedure, a new cycle of rigid body re¢nement was
conducted leading to an Rfactor of 0.328. The non-crystallographic
symmetry (NCS) operations were recalculated and strictly imposed
throughout the subsequent model re¢nement. The 8-fold NCS ensures
an excellent ratio of re¢ned parameters per observation, despite the
relatively low completeness of the dataset. The use of strict NCS
constraints in the re¢nement of protein structures has been strongly
recommended [31], to re£ect the widely observed fact that identical
sequences correspond to identical structures. To carefully scrutinise
this assumption in the present study, in all steps of the re¢nement
both averaged and non-averaged electron density maps for all eight
molecules in the unit cell were simultaneously displayed in order to
identify possible regions of discrepancies, nothing being found to jus-
tify any independent re¢nement.
Six re¢nement cycles of simulated annealing with temperatures
ranging from 3000 K to 300 K with 50 K steps, followed by positional
re¢nement, group B-factor re¢nement and ¢nally individual B-factors
re¢nement were performed. At this stage the NAD cofactor could be
built into the remaining electron density. Some water molecules were
also assigned from di¡erence Fourier maps, located with the program
PICKWATER from CCP4 [28]. Unlike the T. brucei crystal structure,
no sulphate or phosphate ions were found at the active site. There-
fore, the ¢nal model of the re¢ned glycosomal TcGAPDH monomer
has 359 residues, 1 NAD molecule and 90 water molecules. Some of
the C-terminal residues did not show electron density for the side
chains and were re¢ned with zero occupancies for all side chain atoms
beyond CL. The ¢nal Rfactor was 0.201 and the Rfree 0.223 (10% of
re£ections were used in the calculation of Rfree). This comparatively
low value of the Rfree can be correlated to the 8-fold NCS used
throughout the re¢nement, although still an indicator of the unbiasing
of the re¢nement [29]. Atomic co-ordinates have been submitted for
deposition at the Brookhaven data base.
3. Results and discussion
3.1. Quality of the structure
The use of 8-fold strict NCS throughout the structure re-
¢nement has contributed to produce very good electron den-
sity for the available resolution, with the exception of the loop
comprising residues 66^76 and some residues at the N- and C-
termini. An example of the quality of the electron density is
presented in Fig. 1.
The rms deviations from ideality for the ¢nal structure are
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0.009 Aî in bond lengths, 1.639‡ for bond angles and 25.20‡
for dihedral angles. The average temperature factor values for
the main chain and side chain atoms of the 359 residues are
22.9 Aî 2 and 27.0 Aî 2, respectively. The torsion angles for
99.7% of the residues are in the favourable regions in the
Ramachandran diagram [32]. Val255 is the only residue found
in a unfavourable region, with torsion angles of P= 87‡ and
B= 125‡. This residue is located in a loop between two con-
secutive L strands. The unfavourable conformation of this
residue is conserved in all other GAPDH structures available,
and is probably maintained in order to contribute to the cor-
rect positioning of the active residue Cys166 and the nicotina-
mide ring of the NAD cofactor. As shown in Fig. 2, the side
chain of Cys166 is in Van der Waals contact with the CL of
Asn335, whose side chain oxygen forms a hydrogen bond with
the main chain nitrogen of Val255. This hydrogen bond stabil-
ises the asparagine rotamer such that its side chain nitrogen is
in the correct orientation to donate a second hydrogen bond
to the amide of the incoming NAD during catalysis.
3.2. Description of the structure
The Tc-GAPDH tetramer has four subunits arranged with
local 222 symmetry. Each subunit is composed of two do-
mains: the N-terminal or NAD binding domain and the
C-terminal or catalytic domain. The N-terminal domain con-
tains approximately 150 residues comprised of two typical
Rossmann folds forming a 6-stranded parallel L-sheet sur-
rounded by K-helices on both sides. This domain contains
the loop formed by residues 66^76, found only in the GAPDH
of the Trypanosomatidae family (T. cruzi, T. brucei, L. mex-
FEBS 19921 11-3-98
Fig. 1. Stereo view of a slab of the ¢nal (2Fo3Fc) electron density map contoured at a level of 3c showing a region of L sheet centred on
Leu260. Figure produced using the graphics program O [30].
Fig. 2. Stereo view of the active site showing the side chain of the catalytic cysteine (Cys166) in Van der Waals contact with Asn335, whose side
chain amide forms hydrogen bonds simultaneously with the main chain nitrogen of Val255 and the nicotinamide ring of the NAD cofactor.
Val255 adopts a disallowed main chain conformation which is observed in all other GAPDH structures and probably related to the need to ori-
entate correctly the side chain of Asn335 in order to receive the incoming cofactor. The ¢gure was produced using the program MOLSCRIPT
[33].
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icana). The catalytic domain is of the K/L class and includes
the essential residues for the catalytic activity, Cys166 and
His194.
The structures of GAPDH from T. cruzi and T. brucei are
very similar, as expected from their high sequence identity
(90%). The superposition of the two structures has an rms
deviation of 0.53 Aî , for all CKs. Some di¡erences occur at
the N- and C-terminal regions, which were partially disor-
dered in the T. brucei structure, and could be better inter-
preted in the current study.
3.3. NAD+ binding site
The binding site of the adenosine ring of the NAD cofac-
tor has been studied in T. brucei GAPDH and explored as a
good target for rational drug design [7], mainly because of
important di¡erences between the parasite and the homolo-
gous human enzyme.
In the cofactor binding site, two regions could be explored
for speci¢c inhibitor design. In one of them, the presence of
residues Leu113 and Gln91 in T. brucei GAPDH, results in
di¡erences in polarity and volume when compared with the
corresponding residues in the human enzyme. Compounds
have been designed based on adenosine derivatives that aim
to exploit these di¡erences [7]. We ¢nd that in this region T.
cruzi GAPDH is structurally conserved with respect to the
related T. brucei enzyme and therefore could also be a good
target site for the design of speci¢c inhibitors for Chagas’
disease.
The other region that was identi¢ed as a good target is the
interface between two neighbouring subunits of the active
tetramer and also close to the binding site of the adenosine
moiety of the NAD cofactor. In this region, a hydrophobic
pocket of approximately 10 Aî width is formed in the trypa-
nosomal enzyme which is essentially absent in the human
enzyme, due to a di¡erence in the course of the main chain
caused by the presence of Pro190. The residues that participate
in this pocket are Met38, Val205 and Asp39 in T. cruzi, which
are replaced by Phe36, Pro190 and Ile37 in the human enzyme.
Compounds that could still ¢t the NAD binding site but
which possess bulkier substituents capable of exploiting the
adjacent hydrophobic pocket in the parasite enzyme would
possibly have little a⁄nity for human GAPDH, leading to
potential speci¢c inhibitors. With this strategy, adenosine de-
rivatives were designed, synthesised and kinetically character-
ised with respect to the enzymes from T. brucei and L. mex-
icana [7], showing good a⁄nity and selectivity when compared
with the human enzyme.
In the T. cruzi enzyme, the hydrophobic pocket is slightly
more closed than in the T. brucei structure, being only 9 Aî
wide. This could be a consequence of the absence of ions
bound to the active site, as discussed in the following section,
which might hinder the binding of compounds designed based
on the T. brucei structure. The T. cruzi structure, in fact,
should represent the in vivo condition in which the inhibitor
would normally encounter the target enzyme, i.e. with neither
substrate nor inorganic phosphate bound.
3.4. The catalytic site
The catalytic site is composed of the region involving the
nicotinamide moiety of the NAD+ cofactor and the residues
that participate in catalysis. This region has not yet been ex-
ploit for structure-based drug design, mainly because it shows
high sequence and structural conservation as a consequence of
the selective pressure for activity.
A singular feature of the present structure is the fact that
the enzyme has been crystallised in the absence of phosphate
or sulphate ions and therefore with an empty active site. No
ordered water molecules were identi¢ed within the active site
pocket. As a consequence, Arg249, essential for the stabilisa-
tion of charges around the Ps binding site, has shown a large
conformational change. When compared with the structure of
B. stearothermophilus (1.8 Aî resolution), this transition results
in a total displacement of 5.2 Aî in the position of the Ch atom
of the guanidinium moiety, which is then in position to form a
salt bridge to residue Asp210. This has pointed to a possibly
important gating mechanism to regulate the binding of the
substrate to the active site and the release of the product after
the completion of the reaction. Indeed, analysis of several
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Fig. 3. Stereo view of the active site of T. cruzi GAPDH (in bold) superimposed on that of B. stearothermophilus, showing the large di¡erence
in the Arg249 side chain conformation. The sulphate ions encountered in the B. stearothermophilus structure which correspond to the substrate
and inorganic phosphate binding sites are indicated as Ps and Pi respectively. In T. cruzi, in the absence of anions, Arg249 has swung out of
the active site and forms a salt bridge to Asp210 whilst in B. stearothermophilus it points towards the substrate phosphate forming hydrogen
bonds with Thr197 and Gln200. The ¢gure was produced using MOLSCRIPT [33].
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other GAPDHs with known 3D structures have shown the
conservation of this aspartic acid residue, in position to
form a salt bridge to the arginine residue. In the active site
of the structures of the human and duck enzymes, not only
the Asp residue has been substituted by Leu, but a comple-
mentary substitution is also observed, i.e. Gly213 in T. cruzi is
replaced by Asp. As a result, the mammalian and avian en-
zyme structures show the carboxylate of the Asp side chain to
approach approximately the same position as Asp210 in T.
cruzi. This is suggestive that Asp197 in human GAPDH (the
homologue of Gly213 in T. cruzi) may play a similar role to
that of Asp210 in the parasite enzyme in stabilising the argi-
nine in the absence of substrate. Fig. 3 compares the struc-
tures of T. cruzi and L. mexicana in this region highlighting
the conformational change of Arg249. Two recently published
structures of GAPDH, from E. coli and T. aquaticus, were
also crystallised without anions bound to the active site. In
the case of E. coli, Arg231 (equivalent to Arg249 in T. cruzi)
was found to be in two alternate positions in one of the
monomers in the asymmetric unit and in the salt-bridged con-
formation in the other. These data indicate the high £exibility
of the side chain of this residue, reinforcing that its movement
could be important in the regulation of the attachment of the
substrate and the release of the reaction product. The T.
aquaticus structure has the side chain of Arg231 in each of
the four monomers of the asymmetric unit in the closed con-
formation, that is, at the position of co-ordination to the
substrate phosphate despite the absence of anions. All the
thermostable structures have a special feature in this respect,
as they all show an extra arginine residue at the active site,
also in position to co-ordinate Ps, as in B. stearothermophilus.
This second Arg residue (Arg195 in B. stearothermophilus) hin-
ders the movement of the side chain of Arg231 (equivalent to
Arg249 in T. cruzi) to form the salt bridge with Asp192, thus
impeding the gating mechanism described above. It is thus
possible that in thermophilic bacteria the Ps binding site is
preformed prior to substrate binding.
3.5. Implications for drug design
These new ¢ndings related to the active site suggest a po-
tential new target for selective inhibition. The substitution of
Asp210 (T. cruzi) by Leu194 (human) suggests that compounds
that partially occupy the active site and at the same time make
polar interactions with the Asp210 side chain could show in-
creased speci¢city for the parasitic enzyme. Alternatively, in
view of the proposed physiologically important gating mech-
anism involving the active site Arg249, any compound that
could speci¢cally interact with Asp210 and therefore interfere
with the salt bridge formed with Arg249, would be a potential
speci¢c inhibitor. Prospective compounds are being designed
and synthesised to evaluate these possibilities.
Acknowledgements: G.O. is a Howard Hughes Medical Institute In-
ternational Scholar. We thank the Fundac°aìo de Amparo aØ Pesquisa
do Estado de Saìo Paulo (Grant 94/0587-9), Programa de Apoio ao
Desenvolvimento Cient|Ł¢co e TecnoloŁgico/SBIO (Grant 62.0137/95.9)
and the World Health Organisation (TDR Grant 940854), and the
European Commission (INCO-DC Programme) for ¢nancial support.
B.G.G. is supported by a grant from the Brazilian National Research
Council and D.H.F.S. has a post-graduate fellowship from FAPESP.
We thank Prof. F. Opperdoes for his kind encouragement and sup-
port throughout this project.
References
[1] World Health Organisation Statistical Information System Web-
site, at http://www.who.ch./whosis/whosis.htm
[2] Kirchho¡, L.V. (1993) New Engl. J. Med. 329, 639^644.
[3] Opperdoes, F.R. (1987) Annu. Rev. Microbiol. 41, 127^151.
[4] Wierenga, R.K., Noble, M.E.M., Vriend, G., Nauche, S. and
Hol, W.G.J. (1991) J. Mol. Biol. 220, 995^1015.
[5] Vellieux, F.M.D., Hajdu, J., Verlinde, C.L.M.J., Groendijk, H.,
Read, R.J., Greenhough, T.J., Campbell, J.W., Kalk, K.H., Lit-
tlechild, J.A., Watson, H.C. and Hol, W.G.J. (1993) Proc. Natl.
Acad. Sci. USA 20, 2355^2359.
[6] Bernstein, B.E., Michels, P.A.M. and Hol, W.G.J. (1997) Nature
385, 275^278.
[7] Verlinde, C.L.M., Callens, M., Van Calenbergh, S., Van Aer-
schot, A., Herdewijn, P., Hannaert, V., Michels, P.A.M., Opper-
does, F.R. and Hol, W.G.J. (1994) J. Med. Chem. 37, 3605^3613.
[8] Verlinde, C.L.M.J., Merrit, T.E.A., Van Den Akker, F., Kim,
H., Feil, I., Delboni, L.F., Mamde, S.C., Sarfaty, S., Petra,
P.H. and Hol, W.G.J. (1994) Protein Sci. 3, 1670^1686.
[9] Engel, J.C., Franke de Cazzulo, B.M., Stoppani, A.O., Cannatta,
J.J. and Cazzullo, J.J. (1987) Mol. Biochem. Parasitol. 26, 1^
10.
[10] Seydoux, F., Bernhard, S., Pfenninger, O., Payne, M. and Mal-
hota, O.P. (1973) Biochemistry 12, 4290^4300.
[11] Duggleby, R.G. and Dennis, D.T. (1974) J. Biol. Chem. 249,
167^174.
[12] Harrigan, P.J. and Trentham, D.R. (1973) Biochem. J. 135, 695^
703.
[13] Segal, H.L. and Boyer, P.D. (1953) J. Biol. Chem. 204, 265^281.
[14] Moras, D., Olsen, K.W., Sabesan, M.N., Buehner, M., Ford,
G.C. and Rossmann, M.G. (1975) J. Biol. Chem. 250, 9137^9162.
[15] Watson, H.C., Duee, E. and Mercer, W.D. (1972) Nature New
Biol. 240, 130.
[16] Skarzynski, T., Moody, P.C.E. and Wonacott, A.J. (1987) J. Mol.
Biol. 193, 171^187.
[17] Korndoºrfer, I., Steipe, B., Huber, R., Tornschy, A. and Jaenicke,
R. (1995) J. Mol. Biol. 246, 511^521.
[18] Tanner, J., Hecht, R.M., Pisegna, M., Seth, D.M. and Krause,
K.L. (1994) Acta Crystallogr. D50, 744^748; PDB access code
1CER.
[19] DueŁe, E., Olivier-Deyris, L., Fanchon, E., Corbier, C., Branlant,
G. and Dideberg, O. (1996) J. Mol. Biol. 257, 814^838.
[20] Barbosa, V.M. (1996) PhD Thesis, University of Saìo Paulo.
[21] Kim, H., Feil, I.K., Verlinde, C.L.M., Petra, P.H. and Hol,
W.G.J. (1995) Biochemistry 34, 14975^14986.
[22] Hannaert, V., Opperdoes, F.R. and Michels, P.A.M. (1995) Pro-
tein Express. Purif. 6, 244^250.
[23] Matheus, B.W. (1968) J. Mol. Biol. 33, 491^497.
[24] Process Program, Instruction Manual of R-AXIS IIC.
[25] Navaza, J. (1994) Acta Crystallogr. A50, 157^163.
[26] Brunger, A.T. (1992) X-PLOR, A System for X-ray Crystallog-
raphy and NMR, Version 3.1, Yale University Press, New Ha-
ven, CT.
[27] Kleywegt, G.J. and Jones, T.A. (1994) Manual do programa
MAMA, University of Uppsala.
[28] CCP4 Program Suite Rotation Function-ALMN (1994) User
Documentation, Daresbury Laboratory.
[29] Kleywegt, G.J. and Jones, T.A. (1994) RAVE, The Manual,
Uppsala.
[30] Jones, T.A. and Kjeldgaard, M. (1993) ‘O’, The Manual, Version
5.9, Uppsala.
[31] Kleywegt, G.J. and Jones, T.A. (1995) Structure 3, 535^540.
[32] Laskowski, R.A., MacArthur, M.W. and Thornton, J.M. (1993)
J. Appl. Crystallogr. 26, 283^291.
[33] Kraulis, P.J. (1991) J. Appl. Crystallogr. 24, 946^950.
FEBS 19921 11-3-98
D.H.F. Souza et al./FEBS Letters 424 (1998) 131^135 135
